Citations (101)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Riad El Fakih, Naeem Chaudhri, Feras Alfraih, Caitlin R Rausch, Kiran Naqvi & Elias Jabbour. (2020) Complexity of chronic-phase CML management after failing a second-generation TKI. Leukemia & Lymphoma 61:4, pages 776-787.
Read now
Read now
Alix Y. L. Zackon, Amy A. Ayers, Katherine A. Yeager, Mary L. Somma, Jonathan W. Friedberg, Christopher R. Flowers & Loretta J. Nastoupil. (2019) Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs. Leukemia & Lymphoma 60:10, pages 2356-2364.
Read now
Read now
Giuseppe Saglio & Elias Jabbour. (2018) First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leukemia & Lymphoma 59:7, pages 1523-1538.
Read now
Read now
Almudena Ribed, Vicente Escudero-Vilaplana, Rosa Maria Romero-Jimenez, Irene Iglesias-Peinado, Ana Herranz-Alonso & Maria Sanjurjo-Saez. (2016) Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents. Expert Opinion on Drug Safety 15:4, pages 427-435.
Read now
Read now
Lisa J. McGarry, Yaozhu J. Chen, Victoria Divino, Shibani Pokras, Catherine R. Taylor, Julie Munakata, Christopher C. Nieset, Hui Huang, Elias Jabbour & Daniel C. Malone. (2016) Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Current Medical Research and Opinion 32:2, pages 289-299.
Read now
Read now
Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe & Susan J. Blalock. (2015) Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Current Medical Research and Opinion 31:2, pages 289-297.
Read now
Read now
Stephen Harnicar & Sherry Mathew. (2014) Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 61-67.
Read now
Read now
Annie Guérin, Lei Chen, Katherine Dea, Eric Q. Wu & Stuart L. Goldberg. (2014) Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Current Medical Research and Opinion 30:7, pages 1345-1352.
Read now
Read now
Chan Shen, Chun-Ru Chien, Daniel M Geynisman, Fabrice Smieliauskas & Ya-Chen T Shih. (2014) A review of economic impact of targeted oral anticancer medications. Expert Review of Pharmacoeconomics & Outcomes Research 14:1, pages 45-69.
Read now
Read now
Rajiv Mallick, Jennifer Cai & Jenifer Wogen. (2013) Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma. Current Medical Research and Opinion 29:12, pages 1701-1708.
Read now
Read now
Annie Guérin, Eric Q. Wu, Vamsi K. Bollu, Denise Williams, Amy Guo, Diego Ponce de Leon & Alfonso Quintas-Cardama. (2013) The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Journal of Medical Economics 16:1, pages 125-133.
Read now
Read now
Marianne Ulcickas Yood, Susan A. Oliveria, Mark Cziraky, Ishan Hirji, Muhammad Hamdan & Catherine Davis. (2012) Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Current Medical Research and Opinion 28:2, pages 213-219.
Read now
Read now
Eric Q. Wu, Annie Guerin, Andrew P. Yu, Vamsi K. Bollu, Amy Guo & James D. Griffin. (2010) Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Current Medical Research and Opinion 26:12, pages 2861-2869.
Read now
Read now
Bijan Borah, Patricia Sacco & Victoria Zarotsky. (2010) Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Current Medical Research and Opinion 26:8, pages 1957-1965.
Read now
Read now
Articles from other publishers (87)
Saima Ahmed & Carmen G. Loiselle. (2023) Patient Adherence to Oral Anticancer Agents: A Mapping Review of Supportive Interventions. Current Oncology 30:12, pages 10224-10236.
Crossref
Crossref
Samantha E. Clark, Zachary A. Marcum, Jerry Radich, Ruth Etzioni & Anirban Basu. (2023) Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients. Journal of Oncology Pharmacy Practice.
Crossref
Crossref
Meng-Jung Wen, Han-Lin Hsu, Chia-Lun Chang, Jou-Han Wang, Chun-Nan Kuo, Yen-Chun Hsin & Elizabeth H. Chang. (2023) Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study. PLOS ONE 18:5, pages e0286333.
Crossref
Crossref
Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro & Jorge E. Cortes. (2022) A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Yi‐Jiun Su, Ming‐Chung Kuo, Tsai‐Yun Chen, Ming‐Chung Wang, Youngsen Yang, Ming‐Chun Ma, Tung‐Liang Lin, Tung‐Huei Lin, Hung Chang, Chieh‐Lin Jerry Teng, Pei‐Ching Hsiao, Chih‐Cheng Chen, Po‐Nan Wang & Lee‐Yung Shih. (2022)
Comparison of molecular responses and outcomes between
BCR::ABL1
e14a2 and e13a2 transcripts in chronic myeloid leukemia
. Cancer Science 113:10, pages 3518-3527.
Crossref
Crossref
Vicente F. Gil-Guillen, Alejandro Balsa, Beatriz Bernárdez, Carmen Valdés y Llorca, Emilio Márquez-Contreras, Juan de la Haba-Rodríguez, Jose M. Castellano & Jesús Gómez-Martínez. (2022) Medication Non-Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential Interventions. International Journal of Environmental Research and Public Health 19:19, pages 12036.
Crossref
Crossref
Ami VyasAndrew DescoteauxStephen KogutMegha A ParikhPatrick J CampbellAmanda GreenKimberly Westrich. (2022) Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims. Journal of Managed Care & Specialty Pharmacy 28:8, pages 831-844.
Crossref
Crossref
Courtney P. Williams, Amy Davidoff, Michael T. Halpern, Michelle Mollica, Kathleen Castro, Benjamin Allaire & Janet S. de Moor. (2022) Cost-Related Medication Nonadherence and Patient Cost Responsibility for Rural and Urban Cancer Survivors. JCO Oncology Practice 18:8, pages e1234-e1246.
Crossref
Crossref
Yu Chien Yang, Ru Yu Huang, Hui Jen Tsai, Po Chih Li, Yi Hsin Yang & Kun Pin Hsieh. (2022) Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study. European Journal of Preventive Cardiology 29:9, pages 1312-1321.
Crossref
Crossref
Claire C. Conley, McKenzie McIntyre, Nicole A. Pensak, Filipa Lynce, Deena Graham, Roohi Ismail-Khan, Katherine Lopez, Susan T. Vadaparampil & Suzanne C. O’Neill. (2022) Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study. Breast Cancer Research and Treatment 192:2, pages 385-399.
Crossref
Crossref
Alessandro Passardi, Flavia Foca, Orazio Caffo, Carlo Alberto Tondini, Alberto Zambelli, Roberto Vespignani, Giulia Bartolini, Francesco Giulio Sullo, Daniele Andreis, Marco Dianti, Claudio Eccher, Enrico Maria Piras & Stefano Forti. (2022) A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial. Journal of Medical Internet Research 24:1, pages e27349.
Crossref
Crossref
Dominic Pilon, Joyce LaMori, Carmine Rossi, Mike Durkin, Isabelle Ghelerter, Xuehua Ke, Marie-Hélène Lafeuille, Lorie Ellis & Patrick Lefebvre. (2022) Medication adherence among patients with advanced prostate cancer using oral therapies. Future Oncology 18:2, pages 231-243.
Crossref
Crossref
Yundeok Kim, Tae-Hwa Go, Jaeyeon Jang, Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee & Jee Hyun Kong. (2021) Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia. The Korean Journal of Internal Medicine 36:6, pages 1450-1458.
Crossref
Crossref
Carole Bandiera, Evelina Cardoso, Isabella Locatelli, Antonia Digklia, Khalil Zaman, Antonella Diciolla, Valérie Cristina, Athina Stravodimou, Aedo Lopez Veronica, Ana Dolcan, Apostolos Sarivalasis, Aikaterini Liapi, Hasna Bouchaab, Angela Orcurto, Jennifer Dotta-Celio, Solange Peters, Laurent Decosterd, Nicolas Widmer, Dorothea Wagner, Chantal Csajka & Marie Paule Schneider. (2021) Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. JMIR Research Protocols 10:6, pages e30090.
Crossref
Crossref
P. M. Lee, C. T. Chang & Z. M. Yusoff. (2020) Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital. International Journal of Clinical Pharmacy 43:1, pages 46-54.
Crossref
Crossref
Aram BabcockAskal Ayalew AliRajesh BalkrishnanAlberto MonteroVakaramoko Diaby. (2020) Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary. Journal of Managed Care & Specialty Pharmacy 26:7, pages 826-831.
Crossref
Crossref
Kiyotaka Yamazaki, Naohito Inagaki, Daniel Moldaver, Ricardo Viana & Shinya Kimura. (2020) Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients. Cancer Science 111:7, pages 2526-2535.
Crossref
Crossref
Hsiao Ling Phuar, Charles E. Begley, Wenyaw Chan & Trudy Millard Krause. (2020) Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia. American Journal of Clinical Oncology 43:7, pages 517-525.
Crossref
Crossref
Ann A Wang, Christopher Tapia, Yasin Bhanji, Christopher Campbell, Daniel Larsen, Derick Gross, Seema Ganatra, Melad Qodsi, Claudia Tellez & Shikha Jain. (2019) Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation. Journal of Oncology Pharmacy Practice 26:2, pages 279-285.
Crossref
Crossref
Ankur A. Dashputre, Katie S. Gatwood & Justin Gatwood. (2020) Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Managed Care & Specialty Pharmacy 26:2, pages 186-196.
Crossref
Crossref
Krish Patel, Vinjamuri S Sudhir, Shaum Kabadi, Joanna C Huang, Sanchita Porwal, Kushan Thakkar & John M Pagel. (2019) Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees. Journal of Oncology Pharmacy Practice 25:8, pages 1897-1906.
Crossref
Crossref
Christine Sawicki, Kayla E. Friend, Ruchik Patel, Jennifer M. Polinski & Surya Singh. (2019) Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1290-1296.
Crossref
Crossref
Hsiao Ling PhuarCharles E. BegleyWenyaw ChanTrudy Millard Krause. (2019) Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1140-1150.
Crossref
Crossref
Michael Lauseker, Roman Gerlach, Wenke Worseg, Torsten Haferlach, Martin Tauscher, Joerg Hasford & Verena S. Hoffmann. (2019) Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population‐based study. European Journal of Haematology 103:4, pages 362-369.
Crossref
Crossref
Nur Mehpare Kocaturk, Yunus Akkoc, Cenk Kig, Oznur Bayraktar, Devrim Gozuacik & Ozlem Kutlu. (2019) Autophagy as a molecular target for cancer treatment. European Journal of Pharmaceutical Sciences 134, pages 116-137.
Crossref
Crossref
Alan Rodrigues Andrade, Daniel da Silva Leitão, Igor Penha Paz, Talitta Ribeiro Evangelista, Vanessa Joia de Mello & Moisés Hamoy. (2019) Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon. Hematology, Transfusion and Cell Therapy 41:2, pages 106-113.
Crossref
Crossref
Avi Leader, Noam Benyamini, Anat Gafter-Gvili, Juliet Dreyer, Bronya Calvarysky, Alina Amitai, Osnat Yarchovsky-Dolberg, Giora Sharf, Eric Tousset, Opher Caspi, Martin Ellis, Itai Levi, Sabina De Geest & Pia Raanani. (2018) Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre–Post Intervention Multicenter Pilot Study. Clinical Lymphoma Myeloma and Leukemia 18:11, pages e449-e461.
Crossref
Crossref
Sandra Cuellar, Michael Vozniak, Jill Rhodes, Nicholas Forcello & Daniel Olszta. (2017) BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Journal of Oncology Pharmacy Practice 24:6, pages 433-452.
Crossref
Crossref
Avi Leader, Anat Gafter-Gvili, Noam Benyamini, Juliet Dreyer, Bronya Calvarysky, Alina Amitai, Osnat Yarchovsky-Dolberg, Giora Sharf, Eric Tousset, Opher Caspi, Martin Ellis, Itai Levi, Pia Raanani & Sabina De Geest. (2018) Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study. Clinical Lymphoma Myeloma and Leukemia 18:9, pages e351-e362.
Crossref
Crossref
Nazia Rashid, Han A Koh, Kathy J Lin, Brian Stwalley & Eugene Felber. (2017) Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system. Journal of Oncology Pharmacy Practice 24:4, pages 253-263.
Crossref
Crossref
Felisa Gonzales, Zhiyuan Zheng & K. Robin Yabroff. (2018) Trends in Financial Access to Prescription Drugs Among Cancer Survivors. JNCI: Journal of the National Cancer Institute 110:2, pages 216-219.
Crossref
Crossref
Chan Shen, Bo Zhao, Lei Liu & Ya-Chen Tina Shih. (2018) Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Cancer 124:2, pages 364-373.
Crossref
Crossref
Michael Stokes, Carolina Reyes, Yu Xia, Veronica Alas, Hans-Peter Goertz & Luke Boulanger. (2017) Impact of pharmacy channel on adherence to oral oncolytics. BMC Health Services Research 17:1.
Crossref
Crossref
Jochen Hefner, Eva-Johanna Csef & Volker Kunzmann. (2017) Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors. Oncology Nursing Forum 44:6, pages E232-E240.
Crossref
Crossref
Sarah L. Belsey, Robin Ireland, Kathryn Lang, Aytug Kizilors, Aloysius Ho, Ghulam J. Mufti, Alessandra Bisquera, Hugues De Lavallade & Robert J. Flanagan. (2017) Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men. Therapeutic Drug Monitoring 39:5, pages 499-504.
Crossref
Crossref
Meghan E. McGrady, James L. Peugh, Gabriella A. Brown & Ahna L. H. Pai. (2017) Spending on Hospital Care and Pediatric Psychology Service Use Among Adolescents and Young Adults With Cancer. Journal of Pediatric Psychology 42:9, pages 1065-1074.
Crossref
Crossref
Jamie M. Jacobs, Nicole A. Pensak, Nora J. Sporn, James J. MacDonald, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel & Joseph A. Greer. (2017) Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer. Journal of Oncology Practice 13:5, pages e474-e485.
Crossref
Crossref
Nathan A. PennellAdam P. DickerChristine TranHeather S. L. JimDavid L. SchwartzEdward J. Stepanski. (2017) mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice. American Society of Clinical Oncology Educational Book:37, pages 144-154.
Crossref
Crossref
Reina Haque, Jiaxiao Shi, Joanie Chung, Xiaoqing Xu, Chantal Avila, Christopher Campbell, Syed A. Ahmed, Lei Chen & Joanne E. Schottinger. (2017) Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. Journal of the American Pharmacists Association 57:3, pages 303-310.e2.
Crossref
Crossref
Tomasz Sacha, Joanna Góra-Tybor, Ewa Wąsak-Szulkowska, Sławomira Kyrcz-Krzemień, Ewa Mędraś, Rafał Becht, Grażyna Bober, Aneta Kotowska, Joanna Wącław & Andrzej Hellmann. (2017) Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study. Clinical Lymphoma Myeloma and Leukemia 17:5, pages 283-295.
Crossref
Crossref
Zhiyuan Zheng, Xuesong Han, Gery P. GuyJrJr, Amy J. Davidoff, Chunyu Li, Matthew P. Banegas, Donatus U. Ekwueme, K. Robin Yabroff & Ahmedin Jemal. (2017) Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer 123:8, pages 1453-1463.
Crossref
Crossref
Laura A. Fennimore & Pamela K. Ginex. (2017) Oral Agents for Cancer Treatment. Nursing Clinics of North America 52:1, pages 115-131.
Crossref
Crossref
Dominick Latremouille-Viau, Annie Guerin, Patrick Gagnon-Sanschagrin, Katherine Dea, Benjamin G. Cohen & George J. Joseph. (2017) Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. Journal of Managed Care & Specialty Pharmacy 23:2, pages 214-224.
Crossref
Crossref
Karyn Ruiz-Cordell, Steven Haimowitz, Linda Gracie-King & Deborah Middleton. (2016) Optimizing the Use of TKIs in the Management of Chronic Myelogenous Leukemia. Clinical Lymphoma Myeloma and Leukemia 16:8, pages 442-446.
Crossref
Crossref
Joseph A. Greer, Nicole Amoyal, Lauren Nisotel, Joel N. Fishbein, James MacDonald, Jamie Stagl, Inga Lennes, Jennifer S. Temel, Steven A. Safren & William F. Pirl. (2016) A Systematic Review of Adherence to Oral Antineoplastic Therapies. The Oncologist 21:3, pages 354-376.
Crossref
Crossref
Alix E. Hall, Chris Paul, Jamie Bryant, Marita C. Lynagh, Philip Rowlings, Anoop Enjeti & Hannah Small. (2016) To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Critical Reviews in Oncology/Hematology 97, pages 247-262.
Crossref
Crossref
Marie Barillet, Virginie Prevost, Florence Joly & Bénédicte Clarisse. (2015) Oral antineoplastic agents: how do we care about adherence?. British Journal of Clinical Pharmacology 80:6, pages 1289-1302.
Crossref
Crossref
Stuart L. Goldberg. (2015) Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities. Clinical Lymphoma Myeloma and Leukemia 15:12, pages 711-714.
Crossref
Crossref
Kazuhisa Hosoya, Sakiko Mochinaga, Akiko Emoto, Hiromi Yokoo, Hideaki Tokushima, Masayoshi Egoshi, Naoko Sueoka-Aragane & Shinya Kimura. (2015) Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. International Journal of Clinical Oncology 20:6, pages 1203-1210.
Crossref
Crossref
Lei Chen & Eric Q. Wu. (2015) Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. Journal of Managed Care & Specialty Pharmacy 21:11, pages 1088-1089.
Crossref
Crossref
Kevin B. Knopf, Victoria Divino, Lisa McGarry, Yaozhu J. Chen, Shibani Pokras, Julie Munakata, Catherine Taylor, Daniel Ng, Christopher Nieset & Hui Huang. (2015) Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 15:11, pages e163-e171.
Crossref
Crossref
Kristin R Anderson, Carole R Chambers, Nadine Lam, Patrick S Yau, Frances Cusano, M Lynn Savoie & Naureen Sheikh. (2014) Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. Journal of Oncology Pharmacy Practice 21:1, pages 19-25.
Crossref
Crossref
Masako Yokoo, Yasushi Kubota, Yoko Tabe & Shinya Kimura. (2015) Comparative Study of the Anti-leukemic Effects of Imatinib Mesylate, Glivec™ Tablet and Its Generic Formulation, OHK9511. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 38:3, pages 411-416.
Crossref
Crossref
Philippe Barthélémy, Irène Asmane-De la Porte, Nicolas Meyer, Brigitte Duclos, Sebastian Serra, Louis-Marie Dourthe, Shanti Amé, Valère Litique, Cathy Giron, Veronica Goldbarg, Luc Fornecker, Elisabeth Quoix & Jean-Emmanuel Kurtz. (2015) Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies. Oncology 88:1, pages 1-8.
Crossref
Crossref
Nelson Hamerschlak, Carmino de Souza, Ana Lúcia Cornacchioni, Ricardo Pasquini, Daniel Tabak, Nelson Spector & Merula Steagall. (2014) Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients. Sao Paulo Medical Journal 133:6, pages 471-479.
Crossref
Crossref
Michael S. Mathisen, Hagop M. Kantarjian, Jorge Cortes & Elias J. Jabbour. (2014) Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Reviews 28:5, pages 179-187.
Crossref
Crossref
Josep Darbà, Lisette Kaskens, Manuel Abecassis, Joao Carrasco, Ricardo Vitorino & Matthew Taylor. (2013) Coste-efectividad de dasatinib frente a dosis altas de imatinib y nilotinib en pacientes con leucemia mieloide crónica resistente a la dosis estándar de imatinib en Portugal. PharmacoEconomics Spanish Research Articles 11:3, pages 73-83.
Crossref
Crossref
Emmanuel Giménez García, M. Angeles Portero, Concepción Boqué, Asunción Echeveste, Raquel de Paz, Santiago del Castillo, Reyes Calzada, Juan Diego González & Valentín García-Gutiérrez. (2014) Análisis del impacto presupuestario tras la comercialización de nilotinib en el tratamiento de primera línea en pacientes con leucemia mieloide crónica de nuevo diagnóstico en España. PharmacoEconomics Spanish Research Articles 11:1, pages 5-14.
Crossref
Crossref
Walid F. Gellad. (2014) Targeted Cancer Therapy: From Bench to Bedside to Patient. Journal of Clinical Oncology 32:4, pages 268-270.
Crossref
Crossref
Stacie B. DusetzinaAaron N. WinnGregory A. AbelHaiden A. HuskampNancy L. Keating. (2014) Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology 32:4, pages 306-311.
Crossref
Crossref
Thomas E. Delea, Alex Kartashov & Puza P. Sharma. (2013) Retrospective Study of the Prevalence, Predictors, and Consequences of Nonadherence With Lapatinib in Women With Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab. Journal of Pharmacy Technology 30:1, pages 21-30.
Crossref
Crossref
Teng-Chou Chen, Li-Chia Chen, Yaw-Bin Huang & Chao-Sung Chang. (2013) Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. International Journal of Clinical Pharmacy 36:1, pages 172-181.
Crossref
Crossref
Maria Helena de Almeida, Laura Fogliatto & Dulce Couto. (2014) Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Revista Brasileira de Hematologia e Hemoterapia 36:1, pages 54-59.
Crossref
Crossref
David Cella, Cindy J. Nowinski & Olga Frankfurt. (2014) The Impact of Symptom Burden on Patient Quality of Life in Chronic Myeloid Leukemia. Oncology 87:3, pages 133-147.
Crossref
Crossref
Avi Leader & Pia Raanani. (2014) Adherence-Related Issues in Adolescents and Young Adults with Hematological Disorders. Acta Haematologica 132:3-4, pages 348-362.
Crossref
Crossref
Vivian G. Oehler. (2013) Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. Hematology 2013:1, pages 176-183.
Crossref
Crossref
Michaël Chabrier, Olivier Bezy, Marie-Ange Mouret, Jacques-Olivier Bay & Isabelle Jalenques. (2013) Impact de la dépression sur l’adhésion aux traitements anticancéreux oraux. Bulletin du Cancer 100:10, pages 1017-1022.
Crossref
Crossref
Jasem Al-Barrak & Winson Y. Cheung. (2013) Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. Supportive Care in Cancer 21:8, pages 2351-2357.
Crossref
Crossref
Kathy L. Schulman, Karina Berenson, Ya-Chen (Tina) Shih, Kathleen A. Foley, Arijit Ganguli, Jonas de Souza, Nicholas A. Yaghmour & Alex Shteynshlyuger. (2013) A Checklist for Ascertaining Study Cohorts in Oncology Health Services Research Using Secondary Data: Report of the ISPOR Oncology Good Outcomes Research Practices Working Group. Value in Health 16:4, pages 655-669.
Crossref
Crossref
Dale L. Bixby. (2013) Managing inadequate responses to frontline treatment of chronic myeloid leukemia: A case-based review. Cancer Treatment Reviews 39:3, pages 241-251.
Crossref
Crossref
S. Dauchy, F. Ellien, A. Lesieur, O. Bezy, D. Boinon, M. Chabrier, C. Charles, S. Dolbeault, F. Joly, A. Heuguerot, L. Lemaitre, J. -L. Machavoine, E. Marx, G. Marx, I. Piollet-Calmette, S. Pucheu, M. Reich & E. Seigneur. (2013) Quelle prise en charge psychologique dans l’après-cancer ?What psychological care should there be after cancer?. Psycho-Oncologie 7:1, pages 4-17.
Crossref
Crossref
Cheryl-Anne Simoneau. (2013) Treating Chronic Myeloid Leukemia. Clinical Journal of Oncology Nursing 17:1, pages E13-E20.
Crossref
Crossref
Chao-Sung Chang, Yi-Hsin Yang, Chien-Ning Hsu & Min-Ting Lin. (2012) Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis. BMC Health Services Research 12:1.
Crossref
Crossref
Javier Pinilla-Ibarz & Ian Flinn. (2012) The expanding options for front-line treatment in patients with newly diagnosed CML. Critical Reviews in Oncology/Hematology 84:2, pages 287-299.
Crossref
Crossref
Linda NicholsJulie Pippins, Lon Castle, Mary Cassler & Courtney Fuller. (2012) Molecular monitoring of chronic myeloid leukemia: a personalized approach to optimizing treatment response. Personalized Medicine 9:7, pages 727-737.
Crossref
Crossref
Elias Jabbour, Giuseppe Saglio, Jerald Radich & Hagop Kantarjian. (2012) Adherence to BCR-ABL Inhibitors: Issues for CML Therapy. Clinical Lymphoma Myeloma and Leukemia 12:4, pages 223-229.
Crossref
Crossref
Adam Gater, Louise Heron, Linda Abetz-Webb, John Coombs, Jeff Simmons, François Guilhot & Delphine Rea. (2012) Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leukemia Research 36:7, pages 817-825.
Crossref
Crossref
Elias J. Jabbour, Hagop Kantarjian, Lina Eliasson, A. Megan Cornelison & David Marin. (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. American Journal of Hematology 87:7, pages 687-691.
Crossref
Crossref
Josep Darbà & Lisette Kaskens. (2013) Análisis coste-efectividad de dasatinib frente a imatinib a dosis alta en el tratamiento de la leucemia mieloide crónica en pacientes resistentes a dosis estándar de imatinib. PharmacoEconomics Spanish Research Articles 9:2, pages 63-71.
Crossref
Crossref
Patricia S. Ault & Sandra L. Allen-Bard. (2012) Implications of improved survival in patients with chronic myeloid leukemia: a nursing perspective. Community Oncology 9:2, pages 56-64.
Crossref
Crossref
Lina Eliasson. (2012) Treatment adherence in chronic myeloid leukemia: a systematic review of the literature. Clinical Practice 9:1, pages 87-100.
Crossref
Crossref
Siu-Fun Wong & Hamid Mirshahidi. (2011) Use of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Management of Patients and Practical Applications for Pharmacy Practitioners. Annals of Pharmacotherapy 45:6, pages 787-797.
Crossref
Crossref
Margaret von Mehren & Nicolas Widmer. (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?. Cancer Treatment Reviews 37:4, pages 291-299.
Crossref
Crossref
Arthur P. Staddon. (2011) Challenges of ensuring adherence to oral therapy in patients with solid malignancies. Community Oncology 8:6, pages 254-262.
Crossref
Crossref
John Hohneker, Shilpa Shah-Mehta & Patricia S. Brandt. (2011) Perspectives on Adherence and Persistence With Oral Medications for Cancer Treatment. Journal of Oncology Practice 7:1, pages 65-67.
Crossref
Crossref
Massimo Breccia, Fabio Efficace & Giuliana Alimena. (2011) Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?. Cancer Letters 300:2, pages 115-121.
Crossref
Crossref
Paul La Rosée & Michael W. Deininger. (2010) Resistance to Imatinib: Mutations and Beyond. Seminars in Hematology 47:4, pages 335-343.
Crossref
Crossref